Core Viewpoint - The company has signed a strategic cooperation agreement to invest up to RMB 370 million in building a commercial production base for advanced CAR-T cell therapy products in Shanghai, aligning with its commercialization efforts for multiple CAR-T therapies [1] Group 1: Investment and Strategic Partnership - The investment will be made through the company's wholly-owned subsidiary, Shanghai Kaixing Diagnostic Technology Co., Ltd., in collaboration with Shanghai Jinguang Enterprise Development Co., Ltd. [1] - The total investment amount is capped at RMB 370 million, indicating a significant commitment to expanding production capabilities [1] Group 2: Product Development and Commercialization - The new production base will support the commercialization of several CAR-T cell therapy products, including the already launched product, Sai Kaize®, and the product under new drug application, CT041 (proposed brand name "Kailimei") [1] - The initiative aims to lay the groundwork for future mass production of various universal CAR-T cell therapy products, such as CT0596 and CT1190B [1] Group 3: Operational and Financial Strategy - The transaction allows the company to avoid large capital expenditures initially, preserving cash flow for core research and market expansion [1] - A buyback mechanism is in place to ensure the company can gain complete control of the assets after long-term operations, maintaining production stability and enhancing asset layout flexibility [1]
科济药业：订立战略合作协议，扩建上海金山CAR-T商业化生产基地